48results about How to "High protein activity" patented technology

The present invention provides a method treating a patient with Fabry disease by determining whether there is an improvement of a surrogate marker that is associated with Fabry disease following administration of a specific pharmacological chaperone of α-galactosidase A. The method includes administering an effective amount of 1-deoxygalactonojirimycn to the individual, wherein the 1-deoxygalactonojirimycin binds to alpha-galactosidase A in an amount effective to increase activity of the alpha-galactosidase A. The present invention also provides a method for monitoring and increasing a therapeutic response of a patient with Fabry disease following administration of a specific pharmacological chaperone of α-galactosidase A by evaluating the effect on the cytoplasmic staining pattern of a cell from the patient, wherein detection of a staining pattern in the cell that is similar to the staining pattern in a cell from a healthy individual indicates that the individual with Fabry disease is a responder.

The present invention provides a method of improving efficiency of a fermentative production of an L-amino acid. To be specific, the present invention provides a process for producing a L-amino acid, comprising culturing a microorganism wherein the activity of the protein described in any one of (1) to (3) below is higher than that of the parent strain in a medium to produce the L-amino acid and accumulate the L-amino acid in the medium, and then collecting the L-amino acid from the medium:

(1) a protein comprising the amino acid sequence shown by any one of SEQ ID NOS:2, 4, 6 and 8

(2) a protein consisting of the amino acid sequence resulting from deletion, substitution or addition of one or more amino acids in the amino acid sequence shown in any one of SEQ ID NOS:2, 4, 6 and 8, and having L-amino acid transport activity

(3) a protein consisting of the amino acid sequence having 80% or more homology to the amino acid sequence shown in any one of SEQ ID NOS:2, 4, 6 and 8, and having L-amino acid transport activity.

The present invention discloses a method for enhancing the activity of a molecule, or for combining individual activities of different molecules, by linking, fusing or otherwise associating the molecule(s) with a self-coalescing element, whereby the chimeric molecule so formed self-assembles into a higher molecular weight aggregate. The present invention also discloses such chimeric molecules per se and to their use in therapeutic, prophylactic and chemical process applications.

The invention relates to a method for separating and purifying soybean agglutinin from soybean whey and belongs to the field of processing of agricultural products and comprehensive utilization of byproducts. The method disclosed by the invention comprises the following steps: (1) pretreating soybean whey; (2) primarily separating soybean whey protein; (3) re-agglomerating the soybean whey protein and poly-anions; and (4) recycling the soybean agglutinin. Raw materials are pretreated, primarily separated and then re-agglomerated to obtain a final protein polysaccharide compound; the final protein polysaccharide compound is ultra-filtered to remove sugar and then is secondarily centrifuged to obtain a protein solution containing purified soybean agglutinin; the protein solution is subjected to vacuum freeze-drying to obtain a high-purity sample of the soybean agglutinin. The method disclosed by the invention can be used for comprehensively utilizing the soybean whey and is low in requirements on equipment, simple to operate and free of environmental pollution; the soybean agglutinin is high in recycle rate, high in purity and high in protein activity and still retains natural physiological activity.

The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against a bacterial species of the genus Streptococcus (e.g., Streptococcus pneumoniae))). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

The present invention is directed to the use of compound 1436 for the induction of weight loss in an obese mammal.

Antibody conjugates of immune-modulatory compounds and pharmaceutical compositions for use in the treatment of disease, such as fibrotic diseases, autoimmune, or autoinflammatory diseases, are disclosed herein. The disclosed conjugates are useful, among other things, in treating fibrotic diseases, autoimmune diseases, or autoinflammatory diseases, such as by modulating TGFβR1, TGFβR2, TNKS, TNIK, or mTOR.

The invention belongs to the technical field of microbial resource utilization, in particular relates to a method for preparing an antibacterial peptide mixed solution generated by lactococcus lactis subsp lactis and lactobacillus sake, and relates to an application of the antibacterial peptide mixed solution in beancurd preservation. The method comprises the following steps of: preserving freshness of beancurd by adopting 10wt% antibacterial peptide mixed solution, and uniformly spraying the antibacterial peptide mixed solution on the surface of a beancurd block in a ratio of adding 2ml of antibacterial peptide mixed solution in every 10g of beancurd. According to the antibacterial peptide mixed solution, the sense score of the beancurd can be effectively prevented from being reduced, the growing speed of spoilage microorganisms can be inhibited, and the growth of total number of bacteria in the beancurd in the storing period can be suspended. Therefore, the antibacterial peptide mixed solution provided by the invention plays an active effect in beancurd preservation, and has better practical value.

The invention provides a chimeric antigen receptor T cell and application thereof. The chimeric antigen receptor T cell expresses chimeric antigen receptors targeting CD19 and PD-L1 at the same time.The chimeric antigen receptor T cell expresses a CD19 CAR structure and a PD-L1 CAR structure at the same time, and after PD-L1 CAR is combined with PD-L1 expressed by a tumor cell, an activation signal can be transmitted intracellularly. Therefore, the chimeric antigen receptor T cell not only can recognize the tumor cells expressing CD19 in a targeted manner, but also can relieve immunosuppression of PD-1 expressed by the tumor cells on the T cells, avoid an immune escape mechanism of the tumor cells and relieve the problem of drug resistance of CAR-T treatment; and a new idea is provided for CAR-T treatment and adoptive feedback immune cell treatment.

The present invention relates to methods of reducing ΔF508-CFTR ubiquitination or degradation, or increasing ΔF508-CFTR processing or function in a CF cell comprising contacting the cell with a therapeutic agent that inhibits NEDD8, FBXO2, and/or SYVN1 expression in the cell.

Disclosed are deglycosylated fragments of a kringle 1-3 region of plasminogen, nucleotides encoding deglycosylated kringle 1-3 region proteins and antibodies specific for deglycosylated kringle 1-3 region proteins. The compositions of the present invention have increased antiangiogenic activity as compared to previously isolated kringle 1-3 region proteins. Also included in the present invention are methods of treating angiogenesis-associated diseases and conditions such as cancer using the compositions described herein.

The invention discloses a method for separating and purifying sea urchin multifunctional actin. The method is characterized by comprising the following steps: (1) taking coelomic fluid of sea urchin, and centrifuging to take the supernatant so as to obtain the coelomic fluid supernatant; (2) taking the coelomic fluid supernatant as a sample to carry out native non-reductive dialysis electrophoresis; (3) carrying out native non-reductive polyacrylamide gel electrophoresis after the dialysis electrophoresis; (4) carrying out gel cutting on the multifunctional actin strip according to the specific color of the sea urchin multifunctional actin strip after the native non-reductive polyacrylamide gel electrophoresis, and recovering the protein in the gel through a gel crushing dissolution and release method so as to obtain the purified sea urchin multifunctional actin. The method has the advantages that (1) the purified sample is simple and rapid to prepare; (2) the reagent and the equipment are simple in requirement, easy to operate, less in step and short in time; (3) the purified sample has high purity and high protein activity.

The present invention relates to the use of selenate or a pharmaceutically acceptable salt thereof in methods and compositions for enhancing the activity of the protein phosphatase PP2A. Methods of reducing phosphorylation of tau protein, inhibiting activity of GSK3 and treating or preventing neurodegenerative diseases are also described.

The present invention provides a method for predicting antimicrobial activity of a candidate protein by determining the correlation between a multidimensional antimicrobial signature and a multidimensional antimicrobial signature model. The invention also is directed to a method for identifying a protein having antimicrobial activity by screening a library of candidate proteins to identify a multidimensional antimicrobial signature. Also provided by the invention is a method for improving the antimicrobial activity of a protein by altering the multidimensional antimicrobial signature of the protein to increase the similarity to a multidimensional antimicrobial signature model.

The invention discloses a recombinant chromatin modified albumin 1A, as well as a coding gene of and an application of the recombinant chromatin modified albumin 1A, wherein the recombinant chromatin modified albumin 1A comprises chromatin modified albumin 1A, the C end of the chromatin modified albumin 1A is connected with His-Tag, the N end of the chromatin modified albumin 1A is connected with a PTD (protein transduction domain) sequence, the amino acid sequence of the PTD sequence is YGRKKRRQRRR, and the amino acid sequence of the recombinant chromatin modified albumin 1A is shown as SEQ ID NO.2. According to the recombinant chromatin modified albumin 1A, an HIS-Tag tag is guided into wild type Chmp1A, so that the structure of the Chmp1A can not be changed, and can be easily purified through a Ni-NTA (nitrilotriacetic acid) Argarose albumen purifying system. The PTD sequence is guided into the wide type Chmp1A, so that the Chmp1A can effectively enter into tumor cell under the guide of the PTD, and the antitumor activity of the Chmp1A can be played.

The invention discloses a PLA2, C1q and THSD7A fusion protein and a construction method and application thereof. The construction method comprises the following steps that S1, PLA2R, THSD7 and C1q nucleotide sequences are sequentially connected to obtain a target gene, C1q is repeated three times, Linker sequences are added between PLA2R and THSD7A, Linker sequences are added between THSD7 and C1q, and Linker sequences are added between adjacent C1q; S2, an eukaryotic KOZAK sequence is added before the target gene, a restriction endonuclease site Bam I is added at the upstream, a Not I enzymedigestion site is added at the downstream, a 6* His tag sequence is added at the C end, and a complete sequence gene is designed according to mammalian cell preference; S3, the complete sequence geneobtained in the step S2 and plasmids are subjected to double enzyme digestion to obtain an enzyme digestion product; S4, the enzyme digestion product obtained in the step S3 is connected through T4 ligase to obtain recombinant plasmids; S5, the recombinant plasmids are expressed in mammalian cells to obtain the PLA2R, C1q and THSD7A fusion protein. The fusion protein constructed by the method canimprove the sensitivity and specificity of a detection kit and reduce missed detection and false detection.

The present invention provides a novel method for stabilizing proteins, by first identifying the proteolytic sites using N- or C-terminal technology, followed by modification of said sites in order to create stabilized proteins, no longer subject to proteolytic cleavage. the method of the invention immediately provides the user with the exact amino acid position of the proteolytic cleavage site in the protein(s) of interest, even in a complex protein sample. This makes the specific modification of such a site much easier and increases the expectation of success as compared to the amount of effort needed, even in a complex protein sample.

The invention provides a preparation method of a milk product with the function of lowering blood pressure. The milk product with the function of lowering blood pressure is prepared by adding a compound of ACE inhibitory peptides prepared by adopting shellfish meat and green tea powder into a milk product; moreover, enzyme utilization rate and extraction rate are improved by the preparation methodso that the ACE inhibitory peptides are high in activity. According to the preparation method, the shellfish meat is fermented by utilizing bacillus subtilis and aspergillus niger; magnetic carbon microspheres are utilized so as to assist to improve activity and purity of the ACE inhibitory peptides, and thus, fermentation rate is improved; and finally, the ACE inhibitory peptides are purified byusing a magnetic silica adsorption column so as to obtain a final product. The ACE inhibitory peptides prepared according to the preparation method are high in activity and inhibition rate, and havea very good effect of lowering blood pressure; and thus, the milk product prepared by adding the ACE inhibitory peptides has a very good effect of lowering blood pressure.